Exploring the Clinicopathological Parameters of HER2 Low Breast Cancers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Age (in years)
研究概览
简要总结
This was a retrospective cohort study which included all histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 at a tertiary care centre.
This study was performed in line with STROCSS criteria. The following clinicopathological data was retrieved from the histopathological records- age, tumor size, nodal involvement, lymphovascular/ perineural invasion, and Bloom Richardson grading.
Routine histopathological processing was done followed by immunohistochemical analysis for ER, PR, HER2, Ki67 and AR. All the cases were categorised into Luminal A, B, Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification. Further, all the cases were categorised into HER2 negative (no staining or incomplete weak membrane staining in ≤10% tumor cells), HER2 3+ (complete membranous staining) and HER2 low (1-2+ staining without amplification on ISH) based on consensus of two pathology consultants. The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •All histologically proven cases of breast cancer in the 2 years from January 2022- December 2023
排除标准
- •Benign breast tumors
结局指标
主要结局
Age (in years)
时间窗: JANUARY 2022- DECEMBER 2023
It will be measured for HER2 low breast cancer patients
Tumor grade (categorised from G1-G3)
时间窗: JANUARY 2022- DECEMBER 2023
This denotes whether tumor is well, modeartely or porrly differentiated. It will be measured for HER2 low breast cancer patients.
Tumor stage (categorised from T1-T4)
时间窗: JANUARY 2022- DECEMBER 2023
This denotes status of stage of tumor- T1, T2, T3, T4. It will be measured for HER2 low breast cancer patients
N stage (categorised from N0-N3)
时间窗: JANUARY 2022- DECEMBER 2023
This denotes status of nodal involevement- N0, N1, N2 or N3. It will be measured for HER2 low breast cancer patients
Androgen receptor expression (Denoted as present or absent)
时间窗: JANUARY 2022- DECEMBER 2023
This denoted the immunohistochemical expression of androgen receptor which would be evaluted in all cases of HER2 low breast cancer
Surrogate molecular classification (Categorised as luminal/ triple negative)
时间窗: JANUARY 2022- DECEMBER 2023
This denoted the molecular classification of breast cancer based on ER, PR, Her2 expression.
次要结局
未报告次要终点
研究者
SANA AHUJA
ASSISTANT PROFESSOR
Vardhman Mahavir Medical College And Safdarjung Hospital